Mounting evidence suggests ARID1A variation is commonly associated with multiple cancers, including gynecologic cancers, urothelial carcinoma, and gastrointestinal cancer (46, 47), with a mutational rate from 3.6 to 45.2% depending on different tumor types (48). This evidence concerns the gene ARID1A and neoplasm.